慢性肾衰竭患者中的高钾血症
高钾血症在慢性肾脏病(CKD)患者中常见,但报告频率因判定方法和CKD严重程度而异。主要风险因素包括较低eGFR、使用RAAS抑制剂、糖尿病、高龄和男性。高钾血症与全因死亡及心血管疾病风险增加相关,新型口服钾结合剂对非紧急治疗有效安全,但长期影响不确定。
要点
- CKD患者高钾血症风险因素包括低eGFR、RAAS抑制剂、糖尿病、高龄和男性。
- 高钾血症与全因死亡和心血管疾病风险增加相关。
- 新型钾结合剂对CKD患者非紧急高钾血症有效安全,但长期获益不确定。
核心结论
- 高钾血症在CKD患者中与不良结局相关,新型钾结合剂可有效治疗但长期影响不确定。
主要发现
- 高钾血症的报告频率因判定方法和CKD严重程度而异。
- 主要风险因素包括较低eGFR、使用RAAS抑制剂、糖尿病、高龄和男性。
- 在糖尿病CKD患者中,使用两种药物抑制RAAS可显著增加高钾血症风险。
- 高钾血症与全因死亡和心血管疾病风险增加相关,独立于合并症、eGFR或酸中毒。
关键数值与推荐
- 在糖尿病CKD患者中,使用两种药物抑制RAAS可显著增加高钾血症风险。
- 聚苯乙烯磺酸钠缺乏高质量疗效数据,且存在罕见但严重的结肠并发症风险。
- 新型口服钾结合剂对CKD患者非紧急高钾血症有效且安全。
临床怎么用
- CKD患者应监测高钾血症风险因素,如低eGFR、RAAS抑制剂使用等。
- 新型钾结合剂可用于CKD患者非紧急高钾血症的治疗,可能允许继续使用RAAS抑制剂。
- 聚苯乙烯磺酸钠应慎用,因缺乏高质量证据且存在结肠并发症风险。
局限性
- 高钾血症频率报告差异大,受判定方法和CKD严重程度影响。
- 新型钾结合剂长期对发病率、死亡率和生活质量的影响不确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Although hyperkalemia is much more common in patients with chronic kidney disease (CKD), the reported frequency of hyperkalemia varies markedly across studies, primarily due to differences in the ascertainment of hyperkalemia and the severity of CKD. Major risk factors for hyperkalemia among CKD patients include lower estimated glomerular filtration rate (eGFR), use of renin-angiotensin-aldosterone system inhibitors (RAASis), diabetes, older age and male gender. The use of two drugs to inhibit RAAS in diabetic CKD markedly increases the risk of hyperkalemia, as demonstrated in large multicenter clinical trials. Hyperkalemia has consistently been associated with an increased risk of adverse events compared with normokalemia, including all-cause mortality and cardiovascular morbidity and mortality. This risk is not explained by differences in comorbidity or estimated GFR, nor concomitant metabolic abnormalities such as acidosis among those with hyperkalemia. Sodium polystyrene sulfonate has been used commonly for decades to treat hyperkalemia in CKD patients, but without any high-quality clinical data to support its efficacy and with an increased risk of rare but serious colonic complications. The newer oral potassium-binding agents, patiromer and sodium zirconium cyclosilicate, have been shown to be effective and safe for the non-emergent treatment of hyperkalemia in CKD patients, including patients treated with RAASis. Although the long-term use of these medications may permit continuation of RAASis in CKD patients with hyperkalemia, the overall impact of this approach (as compared with down-titration of RAASis and/or up-titration of diuretics) on long-term morbidity, mortality and quality of life remains uncertain.
引用
- Seliger SL. Hyperkalemia in patients with chronic renal failure. Nephrol Dial Transplant. 2019. PMID: 31800076. doi:10.1093/ndt/gfz231
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。